As psychedelic therapy continues to move from research settings into public policy and real-world implementation, clinicians are navigating an increasingly complex legislative landscape. New state-level programs, evolving regulatory frameworks, and the possibility of future FDA approval all raise important questions about scope of practice, access, ethics, and professional readiness.

This webinar will explore the current and emerging policy environment shaping psychedelic therapy in the United States, with a focus on how therapists can responsibly prepare for what lies ahead. Attendees will gain clarity on how legislation becomes regulation, what uncertainty is inherent in early-stage programs, and how clinicians can stay informed without needing to become policy experts.

In this webinar, we’ll be joined by Taylor West, Executive Director of the Healing Advocacy Fund (HAF), a national nonprofit organization advancing responsible and equitable psychedelic policy. Taylor brings extensive experience from drug policy reform and public advocacy, including prior leadership roles in cannabis policy, and now works at the intersection of legislation, public education, and systems-level change in psychedelics.

A central part of the discussion will focus on the New Mexico psilocybin program, which has recently been established and is currently in the process of regulatory development. We’ll explore what this moment means for clinicians, what questions remain open as the program takes shape, and how therapists can interpret early signals from the implementation process.

The conversation will also look ahead to broader legislative efforts that HAF is tracking across the country, including how state-level psychedelic programs compare to potential FDA approval pathways. Throughout, we’ll emphasize practical orientation: what therapists should be reading, who they should be following, and how to prepare professionally and ethically for a rapidly shifting field.

This conversation will highlight:

• Key features and open questions in the New Mexico psilocybin program

• How state-level psychedelic legislation typically moves from passage to practice

• Differences between state-regulated programs and FDA approval pathways

• What therapists can do now to stay informed and professionally prepared

• How policy decisions may shape training, access, and clinical roles over time

This session will benefit clinicians, students, educators, and mental health professionals seeking a grounded understanding of psychedelic legislation and its implications for practice.

The webinar will conclude with a live Q&A. A recording will be sent to everyone who registers, so sign up even if you can’t attend live.